The Cancer Letter

Inside information on cancer research and drug development

In Brief

Welela Tereffe named chief medical executive at MD Anderson

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Welela Tereffe was named chief medical executive of MD Anderson Cancer Center.

Tereffe began the position and joined the institution’s Executive Leadership Team Jan. 1. Previously, Tereffe served as the institution’s chief medical officer, a position she held for two years.

In this role, Tereffe will engage physicians and advanced practice providers in the delivery of research-driven clinical care that includes the Texas Medical Center campus, community and academic settings in Texas and MD Anderson Cancer Network. She will work closely with leadership to recruit faculty, promote research excellence and enhance the wellness and development of providers.

“Welela is a servant leader with strong emotional intelligence and drive. She has intimate knowledge of medical practice, extensive understanding of academic health care, and is known for partnering and engaging others,” Peter WT Pisters, president of MD Anderson, said in a statement. “Her commitment to MD Anderson, to our providers and—most importantly—to our patients is undeniable. She is passionate about improving equity in access to safe, quality care, and to reducing disparities in cancer care and outcomes. We welcome her to our Executive Leadership Team.”

Since joining MD Anderson in 2005, Tereffe has earned a Master of Public Health in 2009, and currently she is working toward a Master of Health Care Management at the Harvard School of Public Health.

Table of Contents

YOU MAY BE INTERESTED IN

Capitol Hill

House GOP leaders propose “streamlining” NIH into 15 institutes and centers
Plan calls for slashing ARPA-H, adding oversight to infectious disease research

Two Republican leaders in the House of Representatives have published a “framework” for reforming NIH—consolidating the agency’s 27 institutes and centers into 15—arguing that a fundamental rethinking of NIH’s structure would fix what they describe as a “system rife with stagnant leadership, as well as research duplication, gaps, and misconduct.”
By Matthew Bin Han Ong
Guest Editorial

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi
In the Archives

Two years before the role of EGFR mutations was understood, ODAC recommended accelerated approval of Iressa for NSCLC

On Sept. 24, 2002, the Oncologic Drugs Advisory Committee recommended an accelerated approval for AstraZeneca’s Iressa (gefitinib). The recommendation concluded a meeting where ODAC weighed whether the drug, an EGFR tyrosine kinase inhibitor, could benefit patients with resistant or refractory non-small cell lung cancer as a third-line therapy.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account